Hemlibra
E821686
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Hemlibra canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9806871 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Hemlibra Context triple: [Chugai Pharmaceutical, hasProduct, Hemlibra]
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Hemlibra Target entity description: Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
hemophilia A treatment
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| hasAdministrationFrequency |
every four weeks
ⓘ
every two weeks ⓘ once weekly ⓘ |
| hasAdministrationSetting | can be self-administered after training ⓘ |
| hasApprovalYear | 2017 ⓘ |
| hasATCCode | B02BX06 ⓘ |
| hasBispecificity |
factor IXa-binding
ⓘ
factor X-binding ⓘ |
| hasBlackBoxWarning |
thromboembolism risk when used with activated prothrombin complex concentrate
ⓘ
thrombotic microangiopathy risk when used with activated prothrombin complex concentrate ⓘ |
| hasCommonAdverseEffect |
arthralgia
ⓘ
fever ⓘ headache ⓘ injection site reaction ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasDrugClass | bispecific monoclonal antibody ⓘ |
| hasFDALabelIndication |
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors
ⓘ
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A without factor VIII inhibitors ⓘ |
| hasGenericName | emicizumab ⓘ |
| hasIndication |
hemophilia A
ⓘ
hemophilia A with factor VIII inhibitors ⓘ hemophilia A without factor VIII inhibitors ⓘ prevention of bleeding episodes ⓘ reduction of bleeding episodes ⓘ |
| hasINN | emicizumab ⓘ |
| hasMechanismOfAction |
bridges activated factor IX and factor X
ⓘ
mimics the cofactor function of activated factor VIII ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRouteOfAdministration | subcutaneous ⓘ |
| hasStorageCondition |
protect from light
ⓘ
refrigerated ⓘ |
| hasTarget |
factor IXa
ⓘ
factor X NERFINISHED ⓘ |
| isApprovedBy |
EMA
NERFINISHED
ⓘ
FDA NERFINISHED ⓘ |
| isDevelopedBy | Chugai Pharmaceutical NERFINISHED ⓘ |
| isManufacturedBy | Roche NERFINISHED ⓘ |
| isMarketedBy | Genentech NERFINISHED ⓘ |
| isNotIndicatedFor |
acquired hemophilia A
ⓘ
hemophilia B ⓘ |
| isUsedIn |
adults
ⓘ
children ⓘ infants ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Hemlibra Description of subject: Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.